Cancer Family
Gastric Neoplasm
CI-CAN-00000185Explore in graph →
Non-malignant720 active trials4 approved drugs55 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000185Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05241899 | A Phase II Clinical Study of Fruquintinib Combined With RC48 in the Treatment of Previously Treated HER2-positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (G/GEJ) Cancer | unknown | Phase 2 | 56 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT01889303 | Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 100 | Wuhan UniversityOTHER | 1 |
| Feb 14, 2022 |
| clinicaltrials |
| NCT03939962 | Camrelizumab Combined With FOLFOX Neoadjuvant Therapy for Resectable Gastric and Gastroesophageal Junctional Adenocarcinoma | unknown | Phase 2 | 60 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 26, 2022 | clinicaltrials |
| NCT04062058 | A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer | unknown | Phase 2 | 82 | Jing Jin, M.D.UNKNOWN | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05204173 | Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis | unknown | Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05198856 | Thalidomide Combined With Chemotherapy and Monotherapy for Maintenance Treatment for Her2-negative Advanced GC | unknown | Phase 1 / Phase 2 | 106 | Qilu Hospital of Shandong UniversityOTHER | 0 | Jan 20, 2022 | clinicaltrials |
| NCT04782791 | Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer | unknown | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 0 | Jan 11, 2022 | clinicaltrials |
| NCT05184946 | Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma | unknown | Phase 2 | 72 | The Second Affiliated Hospital of Shandong First Medical UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05113459 | Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018） | unknown | Phase 2 | 40 | Guoxin LiOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT05095636 | Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 102 | Fudan UniversityOTHER | 1 | Oct 27, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT04006821 | PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma | unknown | Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04982939 | Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer | unknown | Phase 2 | 210 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04526470 | Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer | unknown | Phase 1 / Phase 2 | 55 | Seoul National University Bundang HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT05002686 | Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node Metastasis | unknown | Phase 2 / Phase 3 | 60 | Ruijin HospitalOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04890392 | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT05000554 | The Safety and Efficacy of PD-1 Monoantrapical Chemotherapy in the Treatment of Local Advanced Stomach Cancer | unknown | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 11, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04943653 | Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis(IPXELOX) | unknown | Phase 1 / Phase 2 | 61 | Seoul St. Mary's HospitalOTHER | 1 | Jul 6, 2021 | clinicaltrials |
| NCT04948125 | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | unknown | Phase 2 | 20 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04934618 | A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer | unknown | Phase 2 | 85 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04907864 | Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)(MIRACLE) | unknown | Phase 2 | 112 | Kil Yeon LeeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04888663 | Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study) | unknown | Phase 1 / Phase 2 | 50 | Yonsei UniversityOTHER | 1 | May 21, 2021 | clinicaltrials |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | unknown | Phase 2 | 35 | Zhou FuxiangOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT04393584 | FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma(RusGCG-01) | unknown | Phase 2 / Phase 3 | 538 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT04442984 | FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)(IRIGA) | unknown | Phase 2 | 326 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02901301 | Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer | unknown | Phase 1 / Phase 2 | 41 | Yonsei UniversityOTHER | 1 | Apr 6, 2021 | clinicaltrials |
| NCT04826107 | Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer | unknown | Phase 2 | 196 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT04563975 | Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer | unknown | Phase 2 | 54 | Tao ZhangOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04797923 | A Phase II Study of Conversion Surgery After IP Paclitaxel With XELOX Chemotherapy in AGC With Peritoneal Dissemination | unknown | Phase 2 | 43 | Gangnam Severance HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04792515 | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer(CCWSA/OAFLAG) | unknown | Phase 2 | 67 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT04777162 | Tislelizumab Plus Anlotinib for Immunotherapy Resistant Gastrointestinal Cancer | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04781413 | Nab-PTX Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer | unknown | Phase 1 / Phase 2 | 38 | Ruijin HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT03322969 | Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT01359397 | Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer(B-DOCT) | unknown | Phase 2 | — | The Netherlands Cancer InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT04136600 | EGFR Monoclonal Antibody for Advanced Gastric Cancer | unknown | Phase 2 | 100 | Shanghai Changzheng HospitalOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT03154983 | The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 48 | Zhou FuxiangOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT04631757 | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | unknown | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Nov 17, 2020 | clinicaltrials |
| NCT04567069 | Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment | unknown | Phase 1 / Phase 2 | 45 | The Second Hospital of Shandong UniversityOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT04555304 | Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Therapy | unknown | Phase 2 | 81 | Chengdu Kanghong Biotech Co., Ltd.INDUSTRY | 0 | Sep 18, 2020 | clinicaltrials |
| NCT04358341 | Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer | unknown | Phase 2 | 136 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT04410887 | Neoadjuvant Chemotherapy With PISOXO for Locally-invaded-gastric Cancer (LIGC) | unknown | Phase 1 / Phase 2 | 30 | Ruijin HospitalOTHER | 1 | Jun 1, 2020 | clinicaltrials |
| NCT04367025 | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | unknown | Phase 2 | 70 | Chinese PLA General HospitalOTHER | 1 | Apr 29, 2020 | clinicaltrials |
| NCT04152889 | A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 20, 2020 | clinicaltrials |
| NCT04345770 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer | unknown | Phase 2 | 100 | Wuhan UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT04345783 | Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer | unknown | Phase 2 | 30 | Beijing Friendship HospitalOTHER | 1 | Apr 14, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 16, 2022source: clinicaltrials